天疱疮患者利妥昔单抗超级应答者与难治者的特征及治疗结局
单中心回顾性研究纳入205例接受初始利妥昔单抗治疗的天疱疮患者,提出超级应答者(SR)与利妥昔单抗难治者(RRP)的定义;61例(29.8%)为SR、55例(26.8%)为RRP、89例(43.4%)为中等应答者,并识别出各自独立预测因素,48周内治疗中出现的不良事件(TEAE)总体发生率为29.3%。
要点
- 基线PDAI较低、B细胞比例较高及C3直接免疫荧光阴性提示更易成为超级应答者。
- 初始糖皮质激素剂量较高及既往免疫抑制剂使用史提示更易成为利妥昔单抗难治者。
- 48周TEAE总体发生率29.3%,以皮肤黏膜感染为主,各组间无显著差异。
核心结论
- 本研究提出利妥昔单抗治疗天疱疮中超级应答者与难治者的实用定义,并识别出易于获取的基线预测因素,有助于早期识别不同治疗反应患者。
研究设计与样本
- 单中心回顾性研究,分析205例接受初始利妥昔单抗治疗的天疱疮患者基线数据,采用单因素与多因素logistic回归识别独立预测因素。
主要发现
- 205例中61例(29.8%)为超级应答者,55例(26.8%)为利妥昔单抗难治者,89例(43.4%)为中等应答者。
- 超级应答者的独立预测因素为较低基线天疱疮疾病面积指数、较高基线B细胞百分比及C3直接免疫荧光阴性。
- 利妥昔单抗难治者的独立预测因素为较高的初始糖皮质激素剂量及既往免疫抑制剂使用史。
- 48周内TEAE总体发生率为29.3%,主要为皮肤黏膜感染,组间无显著差异。
关键数值与推荐
- 超级应答者、利妥昔单抗难治者与中等应答者的定义由本研究提出,原文摘要未给出具体判定阈值。
- 48周内TEAE总体发生率为29.3%,以皮肤黏膜感染为主。
临床怎么用
- 可依据基线PDAI、B细胞百分比、C3直接免疫荧光、初始激素剂量及既往免疫抑制剂使用史早期预判利妥昔单抗反应类型。
- 对预测为难治者的患者可考虑个体化治疗策略,并在48周内关注皮肤黏膜感染等不良事件。
局限性
- 单中心设计且样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rituximab (RTX) is a first-line treatment for pemphigus, yet responses vary. Standardized definitions for super-responder (SR) and rituximab-refractory patient (RRP) are lacking, and their predictive factors remain unclear. OBJECTIVE: To establish definitions for SR and RRP, compare their baseline characteristics, identify predictive factors, and evaluate the safety profile of RTX treatment over 48 weeks. METHODS: This retrospective study analyzed baseline data from patients with pemphigus receiving initial RTX. Univariate and multivariate logistic regression identified independent predictors for SR and RRP. RESULTS: Of 205 patients, 61 (29.8%) were SRs, 55 (26.8%) RRPs, and 89 (43.4%) moderate responders. Independent predictors for SRs were lower baseline Pemphigus Disease Area Index, higher baseline B-cell percentage, and negative direct immunofluorescence for C3. For RRPs, independent predictors were higher initial dose of corticosteroids and history of prior immunosuppressants use. The overall incidence of Treatment-emergent adverse events (TEAEs) within 48 weeks was 29.3%, primarily cutaneous/mucosal infections, with no significant difference among groups. LIMITATIONS: Single center design and limited sample size. CONCLUSION: This study proposes practical definitions for SR and RRP in RTX-treated pemphigus and identifies distinct, readily obtainable baseline predictors, which may facilitate early identification of patients with differing treatment responses, providing personalized treatment strategies.
引用
- Wu Z, Jiang J, Duan K, et al. Characterization and treatment outcomes of rituximab therapy in super-responders and rituximab-refractory pemphigus patients: A single-center retrospective study. J Am Acad Dermatol. 2025. PMID: 41467875. doi:10.1016/j.jaad.2025.12.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。